1.59
price up icon5.30%   0.08
pre-market  Pre-mercato:  1.64   0.05   +3.14%
loading
Precedente Chiudi:
$1.51
Aprire:
$1.55
Volume 24 ore:
6.18M
Relative Volume:
1.29
Capitalizzazione di mercato:
$315.14M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-0.75
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+38.26%
1M Prestazione:
+60.02%
6M Prestazione:
-18.46%
1 anno Prestazione:
-34.57%
Intervallo 1D:
Value
$1.50
$1.74
Intervallo di 1 settimana:
Value
$1.13
$2.08
Portata 52W:
Value
$0.6925
$3.94

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name
Nome
Esperion Therapeutics Inc
Name
Telefono
734-887-3903
Name
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Name
Dipendente
304
Name
Cinguettio
@esperioninc
Name
Prossima data di guadagno
2025-03-04
Name
Ultimi documenti SEC
Name
ESPR's Discussions on Twitter

Confronta ESPR con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
ESPR
Esperion Therapeutics Inc
1.59 299.28M 116.33M -209.25M -135.49M -2.12
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
150.75 67.73B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.31 45.73B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.70 44.38B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.51 18.97B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
298.14 13.73B 2.99B 1.21B 1.13B 25.06

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-18 Iniziato Goldman Neutral
2024-12-17 Iniziato Cantor Fitzgerald Overweight
2024-06-20 Downgrade BofA Securities Neutral → Underperform
2024-01-03 Downgrade BofA Securities Buy → Neutral
2023-11-20 Ripresa JP Morgan Neutral
2023-08-01 Aggiornamento Northland Capital Under Perform → Market Perform
2023-06-15 Aggiornamento BofA Securities Underperform → Buy
2023-03-16 Downgrade BofA Securities Neutral → Underperform
2023-03-16 Downgrade Northland Capital Market Perform → Under Perform
2023-03-07 Aggiornamento Credit Suisse Underperform → Neutral
2023-02-27 Ripresa BofA Securities Neutral
2023-02-24 Aggiornamento Jefferies Hold → Buy
2023-02-03 Aggiornamento Morgan Stanley Underweight → Equal-Weight
2022-08-03 Downgrade Credit Suisse Neutral → Underperform
2022-05-05 Aggiornamento JP Morgan Underweight → Neutral
2022-03-10 Iniziato H.C. Wainwright Buy
2021-10-19 Downgrade Credit Suisse Outperform → Neutral
2021-10-14 Downgrade Morgan Stanley Equal-Weight → Underweight
2021-05-05 Downgrade Stifel Buy → Hold
2021-04-26 Ripresa Credit Suisse Outperform
2021-03-11 Iniziato Morgan Stanley Equal-Weight
2021-02-12 Downgrade Jefferies Buy → Hold
2021-02-09 Downgrade Goldman Neutral → Sell
2021-01-15 Downgrade BofA Securities Buy → Neutral
2020-11-10 Aggiornamento Credit Suisse Neutral → Outperform
2020-09-29 Ripresa JP Morgan Underweight
2020-08-11 Downgrade Credit Suisse Outperform → Neutral
2020-04-01 Ripresa BofA/Merrill Buy
2020-03-17 Aggiornamento Citigroup Neutral → Buy
2020-02-24 Downgrade Northland Capital Outperform → Market Perform
2020-02-14 Downgrade Citigroup Buy → Neutral
2019-09-16 Aggiornamento Goldman Sell → Neutral
2019-05-29 Downgrade Goldman Neutral → Sell
2019-05-06 Aggiornamento BofA/Merrill Underperform → Neutral
2019-04-26 Aggiornamento Goldman Sell → Neutral
2019-03-13 Aggiornamento JP Morgan Underweight → Neutral
2019-01-07 Reiterato Needham Strong Buy
2018-12-13 Iniziato Goldman Sell
2018-10-29 Aggiornamento Northland Capital Market Perform → Outperform
2018-10-16 Iniziato BTIG Research Buy
2018-08-17 Aggiornamento Citigroup Neutral → Buy
2018-07-11 Downgrade Northland Capital Outperform → Market Perform
2018-05-03 Downgrade JP Morgan Neutral → Underweight
2018-05-02 Downgrade BofA/Merrill Buy → Underperform
Mostra tutto

Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie

pulisher
Jul 28, 2025

How many analysts rate Esperion Therapeutics Inc. as a “Buy”Expert guidance for superior capital growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Why is Esperion Therapeutics Inc. stock attracting strong analyst attentionRapidly growing investment returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How strong is Esperion Therapeutics Inc. company’s balance sheetUnlock powerful portfolio management tools - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Esperion Therapeutics soars amid vague takeover speculation - MSN

Jul 27, 2025
pulisher
Jul 25, 2025

Is Esperion Therapeutics Inc. a good long term investmentHigh-return market picks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Esperion Therapeutics Inc. stockFree Predictions - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Is Esperion Therapeutics Inc. stock a good hedge against inflationFree Popular Stock Recommendations - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Esperion Therapeutics Inc. Stock Analysis and ForecastAccelerated financial growth - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Esperion Therapeutics soars amid vague takeover speculation (ESPR:NASDAQ) - Seeking Alpha

Jul 24, 2025
pulisher
Jul 22, 2025

Esperion to Announce Second Quarter 2025 Financial Results on August 5, 2025 - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Esperion to Report Second Quarter 2025 Financial Results on August 5 - The Manila Times

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Esperion Therapeutics Inc. stock priceUnstoppable profit momentum - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 15, 2025

How Esperion Therapeutics Inc. stock performs during market volatilityHigh Accuracy Alerts - beatles.ru

Jul 15, 2025
pulisher
Jul 09, 2025

Esperion settles litigation with Accord Healthcare - MSN

Jul 09, 2025
pulisher
Jul 08, 2025

Esperion settles litigation with Accord Healthcare (ESPR) - Seeking Alpha

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Therapeutics Settles With Accord Healthcare to Delay Nexletol Generic Version Until 2040 - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Therapeutics Secures Extended NEXLETOL Patent Protection: A Strategic Play for Market Dominance - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Settles Patent Litigation with Accord Healthcare to Protect NEXLETOL Until 2040 - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Reaches Settlement Agreement with Third ANDA Filer - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Esperion Wins Major Patent Battle: NEXLETOL Gains 15+ Years Market Exclusivity in Settlement Deal - Stock Titan

Jul 08, 2025
pulisher
Jul 02, 2025

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Esperion Therapeutics, Inc. (ESPR) - ACCESS Newswire

Jul 02, 2025
pulisher
Jul 01, 2025

Esperion Appoints Craig Thompson to Board of Directors - GlobeNewswire

Jul 01, 2025
pulisher
Jun 27, 2025

Dyslipidemia Market is expected to reach US$ 40.33 Billion - openPR.com

Jun 27, 2025
pulisher
Jun 17, 2025

ESPR: HC Wainwright Reiterates Buy Rating with $16 Price Target - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RFK Racing Teams Up with Esperion for the Wellness Walk at Pocono - Speedway Digest

Jun 17, 2025
pulisher
Jun 16, 2025

Esperion Therapeutics Soars 19.66% on Positive Clinical Data, Debt Restructuring - AInvest

Jun 16, 2025
pulisher
Jun 14, 2025

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha

Jun 14, 2025
pulisher
Jun 13, 2025

Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

ESPR Leadership to Discuss Future Strategies in Upcoming Conference Call | ESPR Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Traders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 07, 2025

Research Analysts Offer Predictions for ESPR Q2 Earnings - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018ESPR - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 04, 2025

Esperion at Jefferies Global Healthcare: Expanding Opportunities - Investing.com Australia

Jun 04, 2025

Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.41
price down icon 0.71%
$14.58
price down icon 2.28%
$9.26
price down icon 1.59%
drug_manufacturers_specialty_generic RDY
$14.70
price up icon 0.20%
$133.71
price up icon 1.19%
$298.14
price down icon 2.09%
Capitalizzazione:     |  Volume (24 ore):